Red Flags Detected

  • Securities Litigation (new) — Two class action lawsuits filed alleging false statements about efzofitimod, with amended complaint adding CFO as defendant in May 2026.
NASDAQ: ATYR aTYR PHARMA INC 10-Q

aTyr faces securities litigation, Phase 3 trial failure, and Japan partnership loss

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 7, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ATYR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.